

Please try another search
Acasti Pharma Inc. is a late-stage specialty pharma company with drug delivery capability and technologies addressing rare and orphan diseases. The Company is targeting three underserved orphan diseases: Subarachnoid Hemorrhage (SAH), Ataxia Telangiectasia (A-T), and Postherpetic Neuralgia (PHN). The Company's lead product candidate includes GTX-104, which is a clinical-stage nanoparticle formulation of nimodipine being developed for IV infusion in SAH patients. The Company's other pipeline products include GTX-102, an oral mucosal spray formulation of betamethasone intended to develop neurological symptoms of A-T, including developing clinical assessments of posture and gait disturbance, and kinetic speech and oculomotor functions. GTX-101 is a topical bio-adhesive film-forming spray of bupivacaine for the treatment of PHN.
Name | Age | Since | Title |
---|---|---|---|
Janelle D'Alvise | 67 | 2016 | President, CEO, Corporate Secretary & Director |
Alex Choi | - | 2022 | Member of Scientific Advisory Board |
Andrew Ducruet | - | 2022 | Member of Scientific Advisory Board |
R. Loch MacDonald | 60 | 2022 | Member of Scientific Advisory Board |
Vimal Kumar Kavuru | 53 | 2021 | Independent Director |
Donald John Olds | 62 | 2018 | Independent Director |
Dariush Mozaffarian | - | - | Member of Scientific Advisory Board |
Michael L. Derby | 49 | 2022 | Independent Director |
Jean-Marie Canan | 66 | 2016 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review